LIRAGLUTIDE ESCALATED TO 3.0 MG REDUCES HEPATIC STEATOSIS DURING 16 WEEKS' TREATMENT IN NON-DIABETIC OBESE PATIENTS

被引：0
|
作者：
Wang, Xiao Jing
Gong, Ping
Zhou, Chenyun
Huang, Chengwu
Lok, U-Wai
Tang, Shanshan
Taylor, Ann
Eckert, Deborah J.
Chen, Shigao
Camilleri, Michael
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
445
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 42 条
  • [31] Liraglutide, a Once-Daily Human GLP-1 Analogue, Reduces Body Weight and Improves Obesity-Related Risk Factors in Obese Non-Diabetic Subjects: a Randomized Placebo-Controlled Trial
    Astrup, Arne
    Van Gaal, Luc
    Rissanen, Aila
    Niskanen, Leo
    Al Hakim, Mazin
    Madsen, Jesper
    Rasmussen, Mads Frederik
    Rossner, Stephan
    OBESITY, 2008, 16 : S64 - S64
  • [32] The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial
    Finer, Nick
    Al Hakim, Mazin
    Van Gaal, Luc
    Astrup, Arne
    Harper, Angela
    Lean, Michael E. J.
    Niskanen, Leo
    Rasmussen, Mads Frederik
    Rissanen, Aila
    Rossner, Stephan
    Savolainen, Markku J.
    OBESITY, 2009, 17 : S108 - S108
  • [33] Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients
    Yu, Mi-Yeon
    Kim, Dong Ki
    Park, Jung Hwan
    Shin, Sung Joon
    Lee, Sang Ho
    Choi, Bum Soon
    Lim, Chun Soo
    Chin, Ho Jun
    PLOS ONE, 2018, 13 (08):
  • [34] Metformin 2550 MG per day in non-diabetic obese patients on a dietary and exercise programme induce greater weight loss without a similar change in metabolic and blood pressure profiles after six months of treatment
    Silva-Nunes, JA
    Gardete-Correia, LMR
    Nunes-Corrêa, JCC
    DIABETOLOGIA, 2002, 45 : A220 - A220
  • [35] Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
    Ristic, Gorica
    Subota, Vesna
    Ristic, Petar
    Stanisavljevic, Dejana
    Ristic, Arsen
    Glisic, Branislava
    Petronijevic, Milan
    Stefanovic, Dusan
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [36] Improved cardiometabolic risk in diabetic and non-diabetic overweight/obese patients with rimonabant treatment: data from RIO-Diabetes, RIO-Europe, RIO-North America and RIO-Lipids
    Finer, N.
    Scheen, A. J.
    Despres, J. P.
    Pi-Sunyer, F. X.
    Van Gaal, L.
    DIABETIC MEDICINE, 2007, 24 : 3 - 4
  • [37] PROPRANOLOL AND HYPERTHYROIDISM - SERUM FREE FATTY-ACIDS AND GLUCOSE-INDUCED INSULIN RELEASE IN NON-DIABETIC THYROTOXIC PATIENTS DURING TREATMENT TO CLINICAL COMPENSATION
    DEMEDEIROS, YS
    ROSENTHAL, D
    PINHO, MOM
    FRANCALANCI, CCP
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (05): : 518 - 523
  • [38] A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG
    Deodhar, A.
    Kivitz, A.
    Magrey, M.
    Walsh, J. A.
    Mease, P. J.
    Greenwald, M.
    Calheiros, R.
    Kianifard, F.
    Elam, C.
    Nagar, K.
    Winseck, A.
    Gensler, L. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 16 - 17
  • [39] Dramatic reductions in hepatic steatosis accompanied by improved HbA1c following a 4-week treatment of obese/diabetic/NAFLD patients with DD01, a novel long-acting GLP-1/glucagon receptor agonist
    Bell, Adam
    To, Dennis
    Karanth, Subbu
    Sosnovtseva, Svetlana
    Lin, Yen-Huei
    Shin, Jaehee
    JOURNAL OF HEPATOLOGY, 2023, 78 : S102 - S103
  • [40] 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients
    Paolo Fiorina
    Roberto Bassi
    Chiara Gremizzi
    Andrea Vergani
    Rossana Caldara
    Alessandra Mello
    Alessandro Del Maschio
    Francesco De Cobelli
    Gianluca Perseghin
    Antonio Secchi
    Acta Diabetologica, 2012, 49 : 133 - 139
12345